FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309331285> ?p ?o ?g. }

• W4309331285 endingPage "84" @default.
• W4309331285 startingPage "76" @default.
• W4309331285 abstract "Several countries started a 2nd booster COVID-19 vaccination campaign targeting the elderly population, but evidence around its effectiveness is still scarce. This study aims to estimate the relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine in the population aged ≥ 80 years in Italy, during predominant circulation of the Omicron BA.2 and BA.5 subvariants. We linked routine data from the national vaccination registry and the COVID-19 surveillance system. On each day between 11 April and 6 August 2022, we matched 1:1, according to several demographic and clinical characteristics, individuals who received the 2nd booster vaccine dose with individuals who received the 1st booster vaccine dose at least 120 days earlier. We used the Kaplan-Meier method to compare the risks of SARS-CoV-2 infection and severe COVID-19 (hospitalisation or death) between the two groups, calculating the relative vaccine effectiveness (RVE) as (1 - risk ratio)X100. Based on the analysis of 831,555 matched pairs, we found that a 2nd booster dose of mRNA vaccine, 14-118 days post administration, was moderately effective in preventing SARS-CoV-2 infection compared to a 1st booster dose administered at least 120 days earlier [14.3 %, 95 % confidence interval (CI): 2.2-20.2]. RVE decreased from 28.5 % (95 % CI: 24.7-32.1) in the time-interval 14-28 days to 7.6 % (95 % CI: -14.1 to 18.3) in the time-interval 56-118 days. However, RVE against severe COVID-19 was higher (34.0 %, 95 % CI: 23.4-42.7), decreasing from 43.2 % (95 % CI: 30.6-54.9) to 27.2 % (95 % CI: 8.3-42.9) over the same time span. Although RVE against SARS-CoV-2 infection was much reduced 2-4 months after a 2nd booster dose, RVE against severe COVID-19 was about 30 %, even during prevalent circulation of the Omicron BA.5 subvariant. The cost-benefit of a 3rd booster dose for the elderly people who received the 2nd booster dose at least four months earlier should be carefully evaluated." @default.
• W4309331285 created "2022-11-26" @default.
• W4309331285 creator A5009879212 @default.
• W4309331285 creator A5012134128 @default.
• W4309331285 creator A5034727258 @default.
• W4309331285 creator A5047354068 @default.
• W4309331285 creator A5051997773 @default.
• W4309331285 creator A5052127281 @default.
• W4309331285 creator A5054916689 @default.
• W4309331285 creator A5061762387 @default.
• W4309331285 creator A5063013270 @default.
• W4309331285 creator A5067287502 @default.
• W4309331285 creator A5068272030 @default.
• W4309331285 creator A5072925758 @default.
• W4309331285 creator A5075398108 @default.
• W4309331285 creator A5079093673 @default.
• W4309331285 creator A5081849216 @default.
• W4309331285 creator A5084378690 @default.
• W4309331285 creator A5084606823 @default.
• W4309331285 creator A5088172137 @default.
• W4309331285 date "2023-01-01" @default.
• W4309331285 modified "2023-10-13" @default.
• W4309331285 title "Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study" @default.
• W4309331285 cites W2298338128 @default.
• W4309331285 cites W3102923342 @default.
• W4309331285 cites W4205716053 @default.
• W4309331285 cites W4206513796 @default.
• W4309331285 cites W4211029192 @default.
• W4309331285 cites W4220678484 @default.
• W4309331285 cites W4220988150 @default.
• W4309331285 cites W4224272611 @default.
• W4309331285 cites W4224816971 @default.
• W4309331285 cites W4226391586 @default.
• W4309331285 cites W4229442811 @default.
• W4309331285 cites W4281397711 @default.
• W4309331285 cites W4281648214 @default.
• W4309331285 cites W4283026725 @default.
• W4309331285 cites W4283365514 @default.
• W4309331285 cites W4283837487 @default.
• W4309331285 cites W4285590921 @default.
• W4309331285 cites W4288737788 @default.
• W4309331285 cites W4289443539 @default.
• W4309331285 doi "https://doi.org/10.1016/j.vaccine.2022.11.013" @default.
• W4309331285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36400660" @default.
• W4309331285 hasPublicationYear "2023" @default.
• W4309331285 type Work @default.
• W4309331285 citedByCount "6" @default.
• W4309331285 countsByYear W43093312852023 @default.
• W4309331285 crossrefType "journal-article" @default.
• W4309331285 hasAuthorship W4309331285A5009879212 @default.
• W4309331285 hasAuthorship W4309331285A5012134128 @default.
• W4309331285 hasAuthorship W4309331285A5034727258 @default.
• W4309331285 hasAuthorship W4309331285A5047354068 @default.
• W4309331285 hasAuthorship W4309331285A5051997773 @default.
• W4309331285 hasAuthorship W4309331285A5052127281 @default.
• W4309331285 hasAuthorship W4309331285A5054916689 @default.
• W4309331285 hasAuthorship W4309331285A5061762387 @default.
• W4309331285 hasAuthorship W4309331285A5063013270 @default.
• W4309331285 hasAuthorship W4309331285A5067287502 @default.
• W4309331285 hasAuthorship W4309331285A5068272030 @default.
• W4309331285 hasAuthorship W4309331285A5072925758 @default.
• W4309331285 hasAuthorship W4309331285A5075398108 @default.
• W4309331285 hasAuthorship W4309331285A5079093673 @default.
• W4309331285 hasAuthorship W4309331285A5081849216 @default.
• W4309331285 hasAuthorship W4309331285A5084378690 @default.
• W4309331285 hasAuthorship W4309331285A5084606823 @default.
• W4309331285 hasAuthorship W4309331285A5088172137 @default.
• W4309331285 hasBestOaLocation W43093312851 @default.
• W4309331285 hasConcept C121332964 @default.
• W4309331285 hasConcept C12590561 @default.
• W4309331285 hasConcept C126322002 @default.
• W4309331285 hasConcept C1276947 @default.
• W4309331285 hasConcept C159654299 @default.
• W4309331285 hasConcept C167135981 @default.
• W4309331285 hasConcept C187212893 @default.
• W4309331285 hasConcept C203014093 @default.
• W4309331285 hasConcept C203165030 @default.
• W4309331285 hasConcept C22070199 @default.
• W4309331285 hasConcept C2779134260 @default.
• W4309331285 hasConcept C2780441014 @default.
• W4309331285 hasConcept C2780801004 @default.
• W4309331285 hasConcept C2908647359 @default.
• W4309331285 hasConcept C3008058167 @default.
• W4309331285 hasConcept C44249647 @default.
• W4309331285 hasConcept C524204448 @default.
• W4309331285 hasConcept C71924100 @default.
• W4309331285 hasConcept C72563966 @default.
• W4309331285 hasConcept C82789193 @default.
• W4309331285 hasConcept C99454951 @default.
• W4309331285 hasConceptScore W4309331285C121332964 @default.
• W4309331285 hasConceptScore W4309331285C12590561 @default.
• W4309331285 hasConceptScore W4309331285C126322002 @default.
• W4309331285 hasConceptScore W4309331285C1276947 @default.
• W4309331285 hasConceptScore W4309331285C159654299 @default.
• W4309331285 hasConceptScore W4309331285C167135981 @default.
• W4309331285 hasConceptScore W4309331285C187212893 @default.
• W4309331285 hasConceptScore W4309331285C203014093 @default.
• W4309331285 hasConceptScore W4309331285C203165030 @default.

• next